The comprehensive GEM ExTra® report filtered out the BRCA1 (V1804D) and instead found FGFR1 amplification and an FGFR1 fusion which may have been driving the tumor and are targetable by several FGFR inhibitors. Here, FGFR1 is linked to neoplasm.